Structure and properties of pharmacologically active polymers
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Although the concept of using pharmacologically active macromolecular compounds as drugs is still regarded with much skepticism for both theoretical and practical reasons, interest in this field has grown in recent years because of the opportunity to take advantage of the specific properties of polymeric materials. For low molecular weight drugs, changes in structure often lead to a loss of specific activity. On the other hand, the properties of macromolecular drugs depend on the structure of the polymer used and this can be varied over a wide range by the incorporation of comonomer units, by the application of polymer‐analogous reactions, or by related structural changes. A new model is presented for pharmacologically active polymers which incorporates the possibility for continuous variation in (a) solubility and toxicity, (b) fixation and removal of active material, and (c) body distribution. Using the new model as a guide, examples of the synthesis and study of the biological activity of various macromolecular drugs are presented in order to emphasize the importance of this cooperative effort between polymer research and therapeutic problems.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The drug-polymer conjugates were introduced in the early work by Helmut Ringsdorf in 1970s to improve drug solubility, toxicity, and body biodistribution, which was followed by extensive studies on the development of drug-polymer conjugates [143, 144].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [144]
Citations
Cites
de Duve, C., & Wattiaux, R. (1966) · Annual Review of Physiology · doi:10.1146/annurev.ph.28.030166.002251 · Cited by 3,033
De Duve, C., De Barsy, T., Poole, B., Trouet, A., Tulkens, P., & Van Hoof, F. (1974) · Biochemical Pharmacology · doi:10.1016/0006-2952(74)90174-9 · Cited by 1,901
Chang, T. M. S. (1964) · Science · doi:10.1126/science.146.3643.524 · Cited by 1,011
Lysosomes in Biology and Pathology
Lagunoff, D. (1974) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1974.03230160059035 · Cited by 887
AN EXAMINATION OF THE CYTOTOXIC EFFECTS OF SILICA ON MACROPHAGES
Allison, A. C., Harington, J. S., & Birbeck, M. (1966) · The Journal of Experimental Medicine · doi:10.1084/jem.124.2.141 · Cited by 871
FACTOR-VIII COMPLEX AND ENDOTHELIAL DAMAGE
Boneu, B., Abbal, M., Plante, J., & Bierme, R. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92650-1 · Cited by 716
de Duve, C. (2008) · Novartis Foundation Symposia · doi:10.1002/9780470715314.ch1 · Cited by 473
DRUG-CARRIER POTENTIAL OF LIPOSOMES IN CANCER CHEMOTHERAPY
Gregoriadis, G., Swain, C. P., Wills, E. J., & Tavill, A. S. (1974) · The Lancet · doi:10.1016/s0140-6736(74)90682-5 · Cited by 401
Poly[N-(2-hydroxypropyl)methacrylamide]—I. Radical polymerization and copolymerization
Kopeček, J., & Baẑilová, H. (1973) · European Polymer Journal · doi:10.1016/0014-3057(73)90063-3 · Cited by 300
Ryser, H. J.-P. (1968) · Science · doi:10.1126/science.159.3813.390 · Cited by 288
Research works printed but not linked: 20
- Lee H., 1971, Handbook for Surgery and Artificial Organs
- Kabaiwanow W., 1972, Plaste Kaut., 19, 886
- Wessel W., 1971, Arzeim. Forsch., 21, 1468
- Ryser H. J. P., 1970, Proc. Fourth Int. Cong. Pharm., 3, 96
- 1965, Silikose Forsch., 6, 213
- Ferruti P., 1966, Med. Lav., 57, 481
- V.Hofmann dissertation University of Mainz 1975.
- Burger A., 1970, Medicinal Chemistry, 1185
- Donaruma L. G., 1974, Prog. Polym. Sci., 4, 18
- G.Franzmann dissertation University of Mainz 1975.
- H.Morawetzet al. in press.
- Ringsdorf H., 1967, Strahlentherapie, 132, 627
- Busch H., 1961, Cancer Res., 21, 271
- H.Ritter dissertation University of Mainz 1975.
- M.Przybylski dissertation University of Mainz 1975.
- Jacob S. W., 1971, Dimethylsulfoxide
- V.Hofmann H.Ringsdorf andG.Muacevic Makromol. Chem. in press.
- Jacques P. J., 1966, Rev. Quest. Sci., 27, 99
- Jacques P. J., 1969, Lysosomes in Biology and Pathology, 395
- Szekerke M., 1972, Neoplasma, 19, 211
Cited by
Items 101–200 of 1,000
Nanomedicine: Clinical Applications of Polyethylene Glycol Conjugated Proteins and Drugs
Parveen, S., & Sahoo, S. K. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645100-00002 · Cited by 189
Polyhydroxyalkanonate derivatives in current clinical applications and trials
Ueda, H., & Tabata, Y. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00037-1 · Cited by 187
Structural and chemical aspects of HPMA copolymers as drug carriers☆
Ulbrich, K., & Šubr, V. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.10.007 · Cited by 186
Carbohydrate-based amphiphilic nano delivery systems for cancer therapy
Liu, K., Jiang, X., & Hunziker, P. (2016) · Nanoscale · doi:10.1039/c6nr04489a · Cited by 186
Polymer therapeutics: Clinical applications and challenges for development
Vicent, M. J., Ringsdorf, H., & Duncan, R. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.08.001 · Cited by 183
Self-citationNanotechnology and Nanomedicine: Going Small Means Aiming Big
Kumar Teli, M., Mutalik, S., & Rajanikant, G. K. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791208992 · Cited by 177
Macromolecular Ferrocene Compounds as Cancer Drug Models
Neuse, E. W. (2005) · Journal of Inorganic and Organometallic Polymers and Materials · doi:10.1007/s10904-004-2371-9 · Cited by 177
Polymer–drug conjugates: towards a novel approach for the treatment of endrocine-related cancer
Duncan, R., Vicent, M. J., Greco, F., & Nicholson, R. I. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.01045 · Cited by 179
“The concept of polymer – anticancer conjugates was first proposed in 1975 (Ringsdorf 1975), and the biological rationale for their design (Duncan & Kopecek 1984, Duncan 1992) and current understanding of the mechanism of action is well documented (Duncan 2003b, 2005a).”
BackgroundTransepithelial and endothelial transport of poly (amidoamine) dendrimers
KITCHENS, K., ELSAYED, M., & GHANDEHARI, H. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.013 · Cited by 177
“The concept of targeted drug delivery systems consisting of drug molecules and targeting moieties attached to a polymeric carrier was first introduced by Ringsdorf [ 1 ].”
BackgroundPolymer encapsulation of ruthenium complexes for biological and medicinal applications
Villemin, E., Ong, Y. C., Thomas, C. M., & Gasser, G. (2019) · Nature Reviews Chemistry · doi:10.1038/s41570-019-0088-0 · Cited by 167
Conjugation of curcumin onto alginate enhances aqueous solubility and stability of curcumin
Dey, S., & Sreenivasan, K. (2014) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2013.08.067 · Cited by 166
“473 Ringsdorf, H. (1975).”
InfluentialKim, Y., Klutz, A. M., & Jacobson, K. A. (2008) · Bioconjugate Chemistry · doi:10.1021/bc700483s · Cited by 168
Hoste, K., De Winne, K., & Schacht, E. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.07.016 · Cited by 165
Polymer therapeutics: Top 10 selling pharmaceuticals — What next?
Duncan, R. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.001 · Cited by 161
“Early contributions are worthy of note; polymers as drugs (especially antibacterial agents and immunomodulators) [16–18], radioprotectants [19], polymer–drug [6,20] and polymer–protein conjugates [21,22], and block copolymermicelles [23].”
BackgroundPolymer Conjugates: Pharmacokinetic Considerations for Design and Development
Duncan, R., & Spreafico, F. (1994) · Clinical Pharmacokinetics · doi:10.2165/00003088-199427040-00004 · Cited by 164
Isakau, H. A., Parkhats, M. V., Knyukshto, V. N., Dzhagarov, B. M., Petrov, E. P., & Petrov, P. T. (2008) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/j.jphotobiol.2008.06.004 · Cited by 162
“An improvement of photophysical and pharmacokinetic parameters of new photosensitizers can be achieved by either chemical or non-covalent modifications of photosensitizing molecules with polymers [1–4].”
BackgroundNanomedicines Based Drug Delivery Systems for Anti-Cancer Targeting and Treatment
Jain, V., Jain, S., & Mahajan, S. C. (2015) · Current Drug Delivery · doi:10.2174/1567201811666140822112516 · Cited by 163
“Ringsdorf’s vision [18] and ‘Trouet and De Duve’s realization pathway for successful lysosome based drug delivery [19] led to the concept of polymeric- drug conjugation for targeted drug delivery to cancer tissues.”
BackgroundBioconjugation in pharmaceutical chemistry
Veronese, F. M., & Morpurgo, M. (1999) · Il Farmaco · doi:10.1016/s0014-827x(99)00066-x · Cited by 159
Antitumoral activity of PEG–gemcitabine prodrugs targeted by folic acid
Pasut, G., Canal, F., Dalla Via, L., Arpicco, S., Veronese, F. M., & Schiavon, O. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.02.002 · Cited by 160
“This approach is known to reduce drug kidney excretion [12,13] and degradation by water or by metabolic enzymes [14], while enhancing the water solubility.”
BackgroundTargeting drugs to mitochondria
Heller, A., Brockhoff, G., & Göpferich, A. M. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.05.014 · Cited by 167
Controlled biodegradability of polymers — a key to drug delivery systems
Kopec̆ek, J. (1984) · Biomaterials · doi:10.1016/0142-9612(84)90062-0 · Cited by 162
Nanomedicine: Novel approaches in human and veterinary therapeutics
Irache, J. M., Esparza, I., Gamazo, C., Agüeros, M., & Espuelas, S. (2011) · Veterinary Parasitology · doi:10.1016/j.vetpar.2011.05.028 · Cited by 175
A review of polysaccharide cytotoxic drug conjugates for cancer therapy
Goodarzi, N., Varshochian, R., Kamalinia, G., Atyabi, F., & Dinarvand, R. (2012) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2012.10.036 · Cited by 154
Polymer Micro‐ and Nanocapsules as Biological Carriers with Multifunctional Properties
Musyanovych, A., & Landfester, K. (2014) · Macromolecular Bioscience · doi:10.1002/mabi.201300551 · Cited by 166
Hyaluronic Acid-Based Nanocarriers for Anticancer Drug Delivery
Fu, C., Cai, X.-Y., Chen, S., Yu, H.-W., Fang, Y. Z., Feng, X.-C., Zhang, L., & Li, C. (2023) · Polymers · doi:10.3390/polym15102317 · Cited by 159
“The concept of macromolecular prodrugs was first introduced by Ringsdorf in 1975 [9] and as since been extensively studied and developed.”
BackgroundCrommen, J. H. L., Schacht, E. H., & Mense, E. H. G. (1992) · Biomaterials · doi:10.1016/0142-9612(92)90028-m · Cited by 151
Thermal Cycling Enhances the Accumulation of a Temperature-Sensitive Biopolymer in Solid Tumors
Dreher, M. R., Liu, W., Michelich, C. R., Dewhirst, M. W., & Chilkoti, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4444 · Cited by 157
Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice
Liu, W., Dreher, M. R., Furgeson, D. Y., Peixoto, K. V., Yuan, H., Zalutsky, M. R., & Chilkoti, A. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.06.026 · Cited by 149
Friend, D. R., & Pangburn, S. (1987) · Medicinal Research Reviews · doi:10.1002/med.2610070104 · Cited by 153
Theory and practice of site-specific drug delivery
Tomlinson, E. (1987) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(87)90001-9 · Cited by 148
Zou, J., Zhang, F., Zhang, S., Pollack, S. F., Elsabahy, M., Fan, J., & Wooley, K. L. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201300235 · Cited by 144
Polymeric carriers for oral uptake of microparticulates
Andrianov, A. K. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00038-6 · Cited by 142
JEONG, Y., SEO, S., Park, I., Lee, H., Kang, I., Akaike, T., & CHO, C. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.02.027 · Cited by 138
Docetaxel Nanotechnology in Anticancer Therapy
Zhao, P., & Astruc, D. (2012) · ChemMedChem · doi:10.1002/cmdc.201200052 · Cited by 150
Biodegradable amphiphilic polymer–drug conjugate micelles
Hu, X., & Jing, X. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903158917 · Cited by 134
“In fact, the concept of ‘polymeric prodrug’ was first proposed by Ringsdorf in 1975 [26].”
BackgroundKopeček, J., & Yang, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.020 · Cited by 130
“De Duve discovered the lysosomotropism of macromolecules [5] and Ringsdorf published a first comprehensive model of the potential of water-soluble polymers as drug carriers [6].”
BackgroundTrigger responsive polymeric nanocarriers for cancer therapy
Kaur, S., Prasad, C., Balakrishnan, B., & Banerjee, R. (2015) · Biomaterials Science · doi:10.1039/c5bm00002e · Cited by 131
Duncan, R., Ringsdorf, H., & Satchi‐Fainaro, R. (2006) · Journal of drug targeting · doi:10.1080/10611860600833856 · Cited by 161
“In fact, it was pioneering work that began to emerge in the 1970s that began to lay the foundations for a clearly defined chemical and biological rational for the design of polymeric drugs, polymer-protein conjugates (Davis 2002) and polymer-drug conjugates (de Duve et al. 1974; Ringsdorf 1975; Gros et al. 1981).”
BackgroundSelf-citationKang, M., Kim, J.-E., & Im, G. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.05.005 · Cited by 133
Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment
David, A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.006 · Cited by 134
Biodegradable drug delivery systems
Wood, D. A. (1980) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(80)90094-0 · Cited by 140
Lammers, T. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.028 · Cited by 136
Polymeric Drug Delivery Systems
Kim, S. W., Petersen, R. V., & Feijén, J. (1980) · Elsevier eBooks · doi:10.1016/b978-0-12-060310-7.50010-9 · Cited by 128
Combination Therapy Strategies for the Treatment of Malaria
Alven, S., & Aderibigbe, B. A. (2019) · Molecules · doi:10.3390/molecules24193601 · Cited by 134
“The polymer–drug conjugate model was suggested by Helmut Ringsdorf in 1975 (Figure 18) [55].”
BackgroundCovalent Polymer-Drug Conjugates
Elvira, C., Gallardo, A., Román, J. S., & Cifuentes, A. (2005) · Molecules · doi:10.3390/10010114 · Cited by 122
“receptor-active components like immunoglobulin, enzymes, hormones or special drugs, as it has been demonstrated in cancer chemotherapy [8].”
BackgroundTargeting of Nanoparticles: Folate Receptor
Kularatne, S. A., & Low, P. S. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-609-2_17 · Cited by 114
Microfluidics: A focus on improved cancer targeted drug delivery systems
Khan, I. U., Serra, C. A., Anton, N., & Vandamme, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.028 · Cited by 130
Li, X., Wen, H., Dong, H., Xue, W., Pauletti, G. M., Cai, X., Xia, W., Shi, D., & Li, Y. (2011) · Chemical Communications · doi:10.1039/c1cc12495a · Cited by 123
Liao, J., Zheng, H., Fei, Z., Lü, B., Zheng, H. S., Li, D., Xiong, X., & Yi, Y. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.03.004 · Cited by 117
Designing polymer conjugates as lysosomotropic nanomedicines
Duncan, R. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350056 · Cited by 117
Nanomaterials engineering for drug delivery: a hybridization approach
Mohammadi, M. R., Nojoomi, A., Mozafari, M., Dubņika, A., Inayathullah, M., & Rajadas, J. (2017) · Journal of Materials Chemistry B · doi:10.1039/c6tb03247h · Cited by 120
Drug Delivery in Cancer Therapy, Quo Vadis?
Lu, Z., & Qiao, P. L. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00037 · Cited by 126
Ernsting, M. J., Tang, W.-L., MacCallum, N., & Li, S. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.061 · Cited by 113
“The design of polymer conjugate architecture is an active discussion in the field, with significant contributions from investigators including Ringsdorf [28], Duncan [18], and Maeda [3].”
BackgroundPolymer-drug conjugates: current status and future trends
Greco, F., & Vicent, M. J. (2007) · Frontiers in bioscience · doi:10.2741/2882 · Cited by 123
Nano-sized polymers and liposomes designed to deliver combination therapy for cancer
Eldar‐Boock, A., Polyak, D., Scomparin, A., & Satchi‐Fainaro, R. (2013) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2013.04.014 · Cited by 118
“The concept of nanomedicines based on synthetic polymers was elaborated by Helmut Ringsdorf in 1975 [53] on the basis of Jatzkewitz [54] and Ushakov [55] work on polymer drugs conjugates.”
BackgroundFirst Poly(2‐oxazoline)s with Pendant Amino Groups
Cesana, S., Auernheimer, J., Jordan, R., Kessler, H., & Nuyken, O. (2006) · Macromolecular Chemistry and Physics · doi:10.1002/macp.200500495 · Cited by 105
Nanoparticles for radiooncology: Mission, vision, challenges
Kunz‐Schughart, L. A., Dubrovska, A., Peitzsch, C., Ewe, A., Aigner, A. M., Schellenburg, S., Muders, M. H., Hampel, S., Cirillo, G., Iemma, F., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.12.010 · Cited by 116
Folate-decorated maleilated pullulan–doxorubicin conjugate for active tumor-targeted drug delivery
Zhang, H., Li, F., Yi, J., Gu, C., Fan, L., Qiao, Y., Tao, Y., Cheng, C., & Wu, H. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.02.006 · Cited by 109
Biosynthetic-Synthetic Polymer Conjugates
van Hest, J. C. M. (2007) · Journal of macromolecular science. Part C, Reviews in macromolecular chemistry and physics/Journal of macromolecular science. Reviews in macromolecular chemistry and physics · doi:10.1080/15583720601109578 · Cited by 139
“This concept was first postulated by Ringsdorf, to overcome problems associated with therapies based on small organic chemotherapeutics, such as lack of selectivity, low solubility, and rapid excretion from the body.(36,37) A polymeric carrier to which the (deactivated) drugs are attached in the side chain can improve…”
BackgroundPolymere Antitumormittel auf molekularer und zellulärer Basis?
Gros, L., Ringsdorf, H., & Schupp, H. (1981) · Angewandte Chemie · doi:10.1002/ange.19810930405 · Cited by 125
Self-citationFrom Defined Reactive Diblock Copolymers to Functional HPMA-Based Self-Assembled Nanoaggregates
Barz, M., Tarantola, M., Fischer, K., Schmidt, M., Luxenhofer, R., Janshoff, A., Théato, P., & Zentel, R. (2008) · Biomacromolecules · doi:10.1021/bm800684b · Cited by 121
Peptide-Based Polymer Therapeutics
Duro‐Castaño, A., Conejos‐Sánchez, I., & Vicent, M. J. (2014) · Polymers · doi:10.3390/polym6020515 · Cited by 122
“Polymer Therapeutics includes five different groups: polymeric drugs, polymers with inherent activity [5,6] polymer-protein conjugates [3,7,8]; polyplexes which are multi-component systems developed as non-viral vectors for gene/small interfering ribonucleic acid (siRNA) delivery [9,10], polymeric micelles where the b…”
BackgroundSynthesis, Radiolabeling, and Bio-imaging of High-Generation Polyester Dendrimers
Parrott, M. C., Benhabbour, S. R., Saab, C., Lemon, J. A., Parker, S., Valliant, J. F., & Adronov, A. (2009) · Journal of the American Chemical Society · doi:10.1021/ja8078175 · Cited by 117
The crucial role of spacer groups in macromolecular prodrug design
Soyez, H., Schacht, E. H., & Vanderkerken, S. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00400-0 · Cited by 118
Synthesis of Hetero-Telechelic α,ω Bio-Functionalized Polymers
Roth, P. J., Jochum, F. D., Zentel, R., & Théato, P. (2009) · Biomacromolecules · doi:10.1021/bm901095j · Cited by 120
Kaur, J., Mishra, V. K., Singh, S. K., Gulati, M., Kapoor, B., Chellappan, D. K., Gupta, G., Dureja, H., Anand, K., Dua, K., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.04.014 · Cited by 106
Syntheses of Click PEG−Dexamethasone Conjugates for the Treatment of Rheumatoid Arthritis
Liu, X.-M., Quan, L., Tian, J., Laquer, F. C., Ciborowski, P. S., & Wang, D. (2010) · Biomacromolecules · doi:10.1021/bm100578c · Cited by 110
Herth, M. M., Barz, M., Moderegger, D., Allmeroth, M., Jahn, M., Thews, O., Zentel, R., & Rösch, F. (2009) · Biomacromolecules · doi:10.1021/bm8014736 · Cited by 113
Polymeric Materials for Theranostic Applications
Wang, Z., Niu, G., & Chen, X. S. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1103-7 · Cited by 103
Polymer–drug conjugates: present state of play and future perspectives
Pang, X., Du, H., Zhang, H.-Q., Zhai, Y., & Zhai, G. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.09.007 · Cited by 101
Anticancer nanoparticulate polymer‐drug conjugate
Feng, Q., & Tong, R. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10033 · Cited by 105
Duncan, R., Cable, H. C., Lloyd, J. B., Rejmanová, P., & Kopec̆ek, J. (1982) · Bioscience Reports · doi:10.1007/bf01122173 · Cited by 101
Carbon dots for cancer nanomedicine: a bright future
Bayda, S., Amadio, E., Cailotto, S., Frión-Herrera, Y., Perosa, A., & Rizzolio, F. (2021) · Nanoscale Advances · doi:10.1039/d1na00036e · Cited by 101
HPMA-based polymer conjugates with drug combination
Krakovičová, H., Etrych, T., & Ulbrich, K. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.03.011 · Cited by 99
York, A. W., Huang, F., & McCormick, C. L. (2010) · Biomacromolecules · doi:10.1021/bm901249n · Cited by 99
Chytil, P., Etrych, T., Koňák, Č., Šírová, M., Mrkvan, T., Říhová, B., & Ulbrich, K. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.06.028 · Cited by 99
Controllable C–H Alkylation of Polyethers via Iron Photocatalysis
Zhang, Z., Li, X., Zhou, D., Ding, S., Wang, M., & Zeng, R. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c01100 · Cited by 101
Liang, L., Lin, S., Dai, W., Lu, J., Yang, T., Xiang, Y., Zhang, Y., Li, R., & Zhang, Q. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.02.020 · Cited by 102
Classes of Materials Used in Medicine
Alexander, H., Brunski, J., Cooper, S. L., Hench, L. L., Hergenrother, R. W., Hoffman, A. S., Kohn, J., Langer, R., Peppas, N. A., Ratner, B. D., et al. (1996) · Elsevier eBooks · doi:10.1016/b978-0-08-050014-0.50007-9 · Cited by 107
Lactose mediated liver-targeting effect observed by ex vivo imaging technology
Ma, P., Liu, S., Huang, Y., Chen, X., Zhang, L., & Jing, X. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.12.019 · Cited by 96
Ernsting, M. J., Tang, W.-L., MacCallum, N., & Li, S. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200284b · Cited by 105
Controlled drug delivery with nanoassemblies of redox-responsive prodrug and polyprodrug amphiphiles
Deng, Z., & Liu, S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.010 · Cited by 94
Barz, M., Luxenhofer, R., Zentel, R., & Kabanov, A. V. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.06.058 · Cited by 94
Polyester Dendrimers: Smart Carriers for Drug Delivery
Twibanire, J. K., & Grindley, T. B. (2014) · Polymers · doi:10.3390/polym6010179 · Cited by 104
“The concept of using high molecular weight polymeric systems as potential drug delivery systems was initially introduced by Ringsdorf [1,2] and Kopeček [3,4].”
BackgroundBiomedical and Biotechnological Applications of Elastin-Like Polypeptides
Simnick, A. J., Lim, D. W., Chow, D., & Chilkoti, A. (2007) · Journal of macromolecular science. Part C, Reviews in macromolecular chemistry and physics/Journal of macromolecular science. Reviews in macromolecular chemistry and physics · doi:10.1080/15583720601109594 · Cited by 114
“24 26 27 In addition to the EPR effect, macromolecular drug carriers are attractive for drug delivery because they have longer plasma half‐lives, reduced normal tissue toxicity, activity against multiple drug resistant cell lines, and the ability to increase the solubility of poorly soluble drugs.”
BackgroundDevelopment of hydroxylated cucurbit[ n ]urils, their derivatives and potential applications
Gao, R. H., Chen, L., Chen, K., Tao, Z., & Xiao, X. (2017) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2017.07.017 · Cited by 93
First Aldehyde‐Functionalized Poly(2‐oxazoline)s for Chemoselective Ligation
Taubmann, C., Luxenhofer, R., Cesana, S., & Jordan, R. (2005) · Macromolecular Bioscience · doi:10.1002/mabi.200500059 · Cited by 86
Polymer-drug conjugates as inhalable drug delivery systems: A review
Marasini, N., Haque, S., & Kaminskas, L. M. (2017) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2017.06.003 · Cited by 101
Ulbrich, K., Koňák, Č., Tuzar, Z., & Kopec̆ek, J. (1987) · Die Makromolekulare Chemie · doi:10.1002/macp.1987.021880604 · Cited by 101
Nuhn, L., Hartmann, S., Palitzsch, B., Gerlitzki, B., Schmitt, E., Zentel, R., & Kunz, H. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201304212 · Cited by 95
Tumor targeting strategies for chitosan-based nanoparticles
Zhang, X., Yang, X., Ji, J., Liu, A., & Zhai, G. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.09.020 · Cited by 97
“first put forward the concept of polymer-drug conjugates, where the agents are covalently conjugated to macromolecules such as a polymer or protein and then self-assemble to form spherical nanoparticles in aqueous conditions [37].”
BackgroundSupramolecular polymeric chemotherapy based on cucurbit[7]uril-PEG copolymer
Chen, H., Chen, Y., Wu, H., Xu, J., Sun, Z., & Zhang, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.02.051 · Cited by 92
Polymere Therapeutika: Konzepte und Anwendungen
Haag, R., & Kratz, F. (2006) · Angewandte Chemie · doi:10.1002/ange.200502113 · Cited by 108
PEGylated drug delivery systems in the pharmaceutical field: past, present and future perspective
Armengol, E. S., Unterweger, A., & Laffleur, F. (2022) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2022.2101062 · Cited by 93
Polymer Conjugates of Photoinducible CO‐Releasing Molecules
Brückmann, N. E., Wahl, M., Reiß, G. J., Kohns, M., Wätjen, W., & Kunz, P. C. (2011) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201100545 · Cited by 90
Polymer–Drug Conjugates for Novel Molecular Targets
Sanchis, J., Canal, F., Lucas-Domínguez, R., & Vicent, M. J. (2010) · Nanomedicine · doi:10.2217/nnm.10.71 · Cited by 89
Poly(N-(2-hydroxypropyl) methacrylamide)-based nanotherapeutics
Tucker, B. S., & Sumerlin, B. S. (2013) · Polymer Chemistry · doi:10.1039/c3py01279d · Cited by 88
Novel folated and non-folated pullulan bioconjugates for anticancer drug delivery
Scomparin, A., Salmaso, S., Bersani, S., Satchi‐Fainaro, R., & Caliceti, P. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.02.012 · Cited by 88
“According to Ehrlich’s “magic bullet” concept Strebhardt and Ullrich, 2008), Ringsdorf’s macromolecular model Ringsdorf, 1975) and the enhanced permeability and retention EPR) effect described by Maeda and Matsumura (Maeda et al., 000), a variety of polymer therapeutics have been designed to…”
BackgroundLjubimova, J. Y., Fujita, M., Ljubimov, A. V., Torchilin, V. P., Black, K. L., & Holler, E. (2008) · Nanomedicine · doi:10.2217/17435889.3.2.247 · Cited by 93
“Drug conjugation to synthetic and biological macromolecules was attempted a long time ago [13,14]; in particular, targeted delivery using immunoglobulin conjugates [15], until the principle of a polymer as a platform for targeted drug delivery was put forth [16].”
BackgroundZhang, L., Chen, W., Tu, G., Chen, X., Lu, Y., Wu, L., & Zheng, D. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s243657 · Cited by 90
Metadata
- Authors
- Ringsdorf, H.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- Corresponding author
- Ringsdorf, Helmut
- Venue
- Journal of Polymer Science: Polymer Symposia
- Publisher
- Wiley
- Published
- 1975-01
- Volume
- 51
- Issue
- 1
- Pages
- 135-153
- ISSN
- 0360-8905 (ISSN-L)
- 1936-0959
- OpenAlex
- W2098279377
- Cited by
- 1,094
- References
- 63
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 34 · 2023: 35 · 2022: 30 · 2021: 35 · 2020: 50 · 2019: 36 · 2018: 29 · 2017: 46 · 2016: 45 · 2015: 47 · 2014: 55 · 2013: 43 · 2012: 48
- FWCI
- 6.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Polymer Science Polymer Symposia (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Chemistry › Organic Chemistry › Advanced Polymer Synthesis and Characterization
- Physical Sciences › Materials Science › Biomaterials › Hydrogels: synthesis, properties, applications
- Keywords
- macromolecular drugs, comonomer incorporation, polymer-analogous reactions, solubility, toxicity, body distribution, polymer synthesis, biological activity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.